Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Nifedipine (Adalat CR, BAYA1040) 40mg BID, Nifedipine, Nifedipine (Adalat, BAYA1040)
Nifedipine/Candesartan · 4 trials · 2 indications
Maximum drug concentration in plasma after dose administration for nifedipine and candesartan
Area under the drug-concentration vs. time curve from time 0 to the last data point for nifedipine and candesartan
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm1 | EXPERIMENTAL | - |
| Arm 2 | ACTIVE_COMPARATOR | - |
| Nifedipine/Candesartan (fixed dose) | EXPERIMENTAL | - |
| Nifedipine/Candesartan (loose) | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Nifedipine (Adalat, BAYA1040) | DRUG | Nifedipine (Adalat, BAYA1040) 40mg twice a day (BID) |
| Nifedipine/Candesartan (BAY 98-7106) | DRUG | Fixed dose combination of 60 mg nifedipine + 32 mg candesartan (1 tablet in one period) |
| Nifedipine (Adalat, BAY A1040) and Candesartan (Atacand, BAY 12-9333) | DRUG | Loose combination of 1 tablet nifedpipine 60mg (Adalat LA) and 2 tablets candesartan 16mg (Atacand) (3 tablets in one period) . |
Inclusion Criteria: * 20 years or older * Japanese male or female * Outpatient with essential hypertension * Patients who are treated with Adalat CR 40 mg od and at least one antihypertensive drug (other than Ca antagonists) for 4 weeks or more before entry in this study Exclusion Criteria: * Pat...